BioScrip (BIOS) in Focus: Stock Adds 5.2% in Session – Tale of the Tape

April 10, 2015 Technicals 0

Zacks

BioScrip Inc. (BIOS) was a big mover last session with its shares rising over 5% on the day. The upside was a result of analyst firm Craig Hallum’s coverage initiation on BioScrip with a "buy" rating and a price target of $7.00, as reported in The Street. The move came on solid volume with far more shares changing hands than in a normal session. The move breaks the recent trend of the company as the stock is now trading above the past one month’s volatile price range of $3.45 to $4.77.

This provider of home infusion and other home care services, and pharmacy benefit management (PBM) services has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.

BioScrip currently holds a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Investors interested in the Drug-Retail industry may consider Diplomat Pharmacy, Inc. (DPLO) which carries a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research

Be the first to comment

Leave a Reply